Tandem Diabetes Care Inc
NASDAQ:TNDM
Tandem Diabetes Care Inc
Revenue
Tandem Diabetes Care Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Tandem Diabetes Care Inc
NASDAQ:TNDM
|
Revenue
$747.7m
|
CAGR 3-Years
14%
|
CAGR 5-Years
32%
|
CAGR 10-Years
38%
|
|
Becton Dickinson and Co
NYSE:BDX
|
Revenue
$19.5B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
9%
|
|
Boston Scientific Corp
NYSE:BSX
|
Revenue
$14.2B
|
CAGR 3-Years
13%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
Stryker Corp
NYSE:SYK
|
Revenue
$20.5B
|
CAGR 3-Years
13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
Abbott Laboratories
NYSE:ABT
|
Revenue
$40.3B
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Revenue
$7.3B
|
CAGR 3-Years
17%
|
CAGR 5-Years
14%
|
CAGR 10-Years
13%
|
Tandem Diabetes Care Inc
Revenue Breakdown
Breakdown by Geography
Tandem Diabetes Care Inc
Total Revenue:
747.7m
USD
|
United States:
554.9m
USD
|
Outside The United States:
192.8m
USD
|
Breakdown by Segments
Tandem Diabetes Care Inc
See Also
What is Tandem Diabetes Care Inc's Revenue?
Revenue
747.7m
USD
Based on the financial report for Dec 31, 2023, Tandem Diabetes Care Inc's Revenue amounts to 747.7m USD.
What is Tandem Diabetes Care Inc's Revenue growth rate?
Revenue CAGR 10Y
38%
Over the last year, the Revenue growth was -7%. The average annual Revenue growth rates for Tandem Diabetes Care Inc have been 14% over the past three years , 32% over the past five years , and 38% over the past ten years .